Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 19 de 19 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
2. Cita con resumen
Lip GYH, Kamath S. Adverse reactions of drugs used to treat arrhythmia. Adv Drug React Bull 2000;201:767-70. [Ref.ID 50835]
3. Cita con resumen
Aronson JK. "Where name and image meet" - the argument for "adrenaline". BMJ 2000;320:506-9. [Ref.ID 49471]
4.Tiene citas relacionadas Cita con resumen
Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 1999;282:790-5. [Ref.ID 46652]
5.
Cannom DS, Prystowsky E N. Management of ventricular arrhythmias. Detection, drugs, and devices. JAMA 1999;281:172-9. [Ref.ID 42516]
6.
Joglar JA, Page RL. Treatment of cardiac arrythmias during pregnancy: safety considerations. Drug Saf 1999;20:85-94. [Ref.ID 42288]
7.
Aziz EE. Drug-induced cardiac failure. Adv Drug React Bull 1997;185:703-6. [Ref.ID 34137]
8.
Anónimo. Drugs for cardiac arrhythmias. Med Lett Drugs Ther 1996;38:75-82. [Ref.ID 29486]
9.
Brooks MM, Gorkin L, Schron EB, Wiklund I, Campion J, Ledingham RB. Morcizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II). Control Clin Trial 1994;15:437-49. [Ref.ID 23269]
10.
Epstein AE, Hallstrom AP, Rogers W J, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG, for the CAST Investigators. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the cardiac arrhythmia trial (CAST). JAMA 1993;270:2451-5. [Ref.ID 20721]
11.
Clyne CA, Estes NAM, Wang PJ. Moricizine. N Engl J Med 1992;327:255-60. [Ref.ID 17847]
12. Cita con resumen
The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33. [Ref.ID 17843]
13. Cita con resumen
Damle R, Levine J, Matos J, Greenberg S, Brooks R, Frumkin W, Goldberger J, Kadish AH. Efficacy and risks of moricizine in inducible sustained ventricular tachycardia. Ann Intern Med 1992;116:375-81. [Ref.ID 17350]
14. Cita con resumen
Somberg JC. The CAST results. J Clin Pharmacol 1990;30:965. [Ref.ID 15933]
15.
Anónimo. Moricizine for cardiac arrhythmias. Med Lett Drugs Ther 1990;32:100-1. [Ref.ID 15832]
16.
Carnes CA, Coyle JD. Moricizine: a novel antiarrhythmic agent. Drug Intell Clin Pharm 1990;24:745-53. [Ref.ID 15325]
18. Cita con resumen
The Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12. [Ref.ID 13424]
19.
Ruskin J N. The Cardiac Arrhytmia Suppression Trial (CAST). N Engl J Med 1989;321:386-8. [Ref.ID 13423]
Seleccionar todas
 
 1 a 19 de 19